Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Protect Cardiomyocytes from Doxorubicin-Induced Cardiomyopathy by Upregulating Survivin Expression Via the MiR-199a-3p-Akt-Sp1/p53 Signaling Pathway

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jul 20

PMID 34281156

Citations 23

Authors

Ji Yoon Lee

Jihwa Chung

Yeongju Byun

Kyoung Hwa Kim

Shung Hyun An

Kihwan Kwon

Affiliations

Soon will be listed here.

Abstract

Cardiotoxicity is associated with the long-term clinical application of doxorubicin (DOX) in cancer patients. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) including exosomes have been suggested for the treatment of various diseases, including ischemic diseases. However, the effects and functional mechanism of MSC-sEVs in DOX-induced cardiomyopathy have not been clarified. Here, MSC-sEVs were isolated from murine embryonic mesenchymal progenitor cell (C3H/10T1/2) culture media, using ultrafiltration. H9c2 cardiac myoblast cells were pretreated with MSC-sEVs and then exposed to DOX. For in vivo studies, male C57BL/6 mice were administered MSC-sEVs intravenously, prior to a single dose of DOX (15 mg/kg, intraperitoneal). The mice were sacrificed 14 days after DOX treatment. The results showed that MSC-sEVs protected cardiomyocytes from DOX-induced cell death. H9c2 cells treated with DOX showed downregulation of both phosphorylated Akt and survivin, whereas the treatment of MSC-sEVs recovered expression, indicating their anti-apoptotic effects. Three microRNAs (miRNAs) (miR 199a-3p, miR 424-5p, and miR 21-5p) in MSC-sEVs regulated the Akt-Sp1/p53 signaling pathway in cardiomyocytes. Among them, miR 199a-3p was involved in regulating survivin expression, which correlated with the anti-apoptotic effects of MSC-sEVs. In in vivo studies, the echocardiographic results showed that the group treated with MSC-sEVs recovered from DOX-induced cardiomyopathy, showing improvement of both the left ventricle fraction and ejection fraction. MSC-sEVs treatment also increased both survivin and B-cell lymphoma 2 expression in heart tissue compared to the DOX group. Our results demonstrate that MSC-sEVs have protective effects against DOX-induced cardiomyopathy by upregulating survivin expression, which is mediated by the regulation of Akt activation by miRNAs in MSC-sEVs. Thus, MSC-sEVs may be a novel therapy for the prevention of DOX-induced cardiomyopathy.

Citing Articles

Mesenchymal stem cell-derived extracellular vesicles for human diseases.

Zhang X, Che X, Zhang S, Wang R, Li M, Jin Y Extracell Vesicles Circ Nucl Acids. 2024; 5(1):64-82.

PMID: 39698413 PMC: 11648454. DOI: 10.20517/evcna.2023.47.

Deciphering the roles of cellular and extracellular non-coding RNAs in chemotherapy-induced cardiotoxicity.

Feng P, Yang F, Zang D, Bai D, Xu L, Fu Y Mol Cell Biochem. 2024; .

PMID: 39485641 DOI: 10.1007/s11010-024-05143-5.

Mesenchymal Stem Cell-Derived Exosomes in Cardioprotection: A Novel Application to Prevent Myocardial Injury.

Yang S, Li J, Tang M, Gao X, Liu W, Wei S Rev Cardiovasc Med. 2024; 23(9):310.

PMID: 39077717 PMC: 11262356. DOI: 10.31083/j.rcm2309310.

Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations.

Tetterton-Kellner J, Jensen B, Nguyen J Adv Drug Deliv Rev. 2024; 211:115361.

PMID: 38901637 PMC: 11534294. DOI: 10.1016/j.addr.2024.115361.

Exosomal miR-9-5p derived from iPSC-MSCs ameliorates doxorubicin-induced cardiomyopathy by inhibiting cardiomyocyte senescence.

Zheng H, Liang X, Liu B, Huang X, Shen Y, Lin F J Nanobiotechnology. 2024; 22(1):195.

PMID: 38643173 PMC: 11032595. DOI: 10.1186/s12951-024-02421-8.

References

Liu J, Wang Y, Cui J, Sun M, Pu Z, Wang C . miR199a-3p regulates P53 by targeting CABLES1 in mouse cardiac c-kit cells to promote proliferation and inhibit apoptosis through a negative feedback loop. Stem Cell Res Ther. 2017; 8(1):127. PMC: 5460483. DOI: 10.1186/s13287-017-0515-4. View

Keller S, Sanderson M, Stoeck A, Altevogt P . Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006; 107(2):102-8. DOI: 10.1016/j.imlet.2006.09.005. View

Oh J, Lee B, Lim G, Lim H, Lee C, Park S . Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition. J Mol Cell Cardiol. 2019; 138:244-255. DOI: 10.1016/j.yjmcc.2019.12.007. View

Latronico M, Catalucci D, Condorelli G . Emerging role of microRNAs in cardiovascular biology. Circ Res. 2007; 101(12):1225-36. DOI: 10.1161/CIRCRESAHA.107.163147. View

Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K . Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004; 110(19):3055-61. DOI: 10.1161/01.CIR.0000148849.51177.97. View

Holmgren G, Synnergren J, Andersson C, Lindahl A, Sartipy P . MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity. Toxicol In Vitro. 2016; 34:26-34. DOI: 10.1016/j.tiv.2016.03.009. View

Gong M, Yu B, Wang J, Wang Y, Liu M, Paul C . Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. Oncotarget. 2017; 8(28):45200-45212. PMC: 5542178. DOI: 10.18632/oncotarget.16778. View

Li X, Liu M, Sun R, Zeng Y, Chen S, Zhang P . Cardiac complications in cancer treatment - A review. Hellenic J Cardiol. 2016; 58(3):190-193. DOI: 10.1016/j.hjc.2016.12.003. View

Si R, Tao L, Zhang H, Yu Q, Zhang R, Lv A . Survivin: a novel player in insulin cardioprotection against myocardial ischemia/reperfusion injury. J Mol Cell Cardiol. 2010; 50(1):16-24. DOI: 10.1016/j.yjmcc.2010.08.017. View

10.

Lee J, Chung J, Kim K, An S, Yi J, Ae Kwon K . Extracorporeal shock waves protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin via the integrin-ILK-Akt-Sp1/p53 axis. Sci Rep. 2019; 9(1):12149. PMC: 6704172. DOI: 10.1038/s41598-019-48470-0. View

11.

Bartlett J, Trivedi P, Pulinilkunnil T . Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol. 2017; 104:1-8. DOI: 10.1016/j.yjmcc.2017.01.007. View

12.

Sayed D, He M, Hong C, Gao S, Rane S, Yang Z . MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem. 2010; 285(26):20281-90. PMC: 2888441. DOI: 10.1074/jbc.M110.109207. View

13.

Zhao J, Tenev T, Martins L, Downward J, Lemoine N . The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000; 113 Pt 23:4363-71. DOI: 10.1242/jcs.113.23.4363. View

14.

Sandhu H, Maddock H . Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clin Sci (Lond). 2013; 126(6):377-400. DOI: 10.1042/CS20120620. View

15.

Vigneron N, Meryet-Figuiere M, Guttin A, Issartel J, Lambert B, Briand M . Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy. Mol Oncol. 2016; 10(7):981-92. PMC: 5423189. DOI: 10.1016/j.molonc.2016.03.005. View

16.

Zhang Y, Liu Y, Liu H, Tang W . Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019; 9:19. PMC: 6377728. DOI: 10.1186/s13578-019-0282-2. View

17.

Seok H, Wang D . The emerging role of microRNAs as a therapeutic target for cardiovascular disease. BioDrugs. 2010; 24(3):147-55. DOI: 10.2165/11535860-000000000-00000. View

18.

Yang W, He Y, Gan L, Zhang F, Hua B, Yang P . Cardiac shock wave therapy promotes arteriogenesis of coronary micrangium, and ILK is involved in the biomechanical effects by proteomic analysis. Sci Rep. 2018; 8(1):1814. PMC: 5788936. DOI: 10.1038/s41598-018-19393-z. View

19.

Wang L, Zhang T, Zhang Y, Bi H, Guan X, Wang H . Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein. Sci Rep. 2016; 6:28399. PMC: 4914971. DOI: 10.1038/srep28399. View

20.

Damiani R, Moura D, Viau C, Caceres R, Henriques J, Saffi J . Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. 2016; 90(9):2063-2076. DOI: 10.1007/s00204-016-1759-y. View